Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Safety and efficacy of azacitidine in myelodysplastic syndromes.

    ... different dosages, treatment schedules, and safety of azacitidine are reviewed. SUMMARY: Azacitidine is the first drug FDA-approved for the treatment of ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.

    ... Azacitidine is currently the only drug to have shown a significant ... However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations ... management of Int-2 and high-risk patients receiving azacitidine. Bone Marrow ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

    ... Lenalidomide and azacitidine each have activity in myelodysplastic syndromes (MDS) ... the efficacy and safety of combination therapy with azacitidine (75mg/m(2)/d x 5 days) and lenalidomide (10mg/d x 21 days (28-day ...

    Research Article last updated 10/01/2012 - 9:58am.

  4. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

    ... months even in the presence of continuous therapy with azacitidine (AZA). Whether p53 expression status known to confer ...

    Research Article last updated 07/07/2014 - 9:27am.

  5. Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia-a wise Liaison?

    ... patients. In fact, hypomethylating agents (HMA) like azacitidine have been successfully used in clinical trials and achieved ... agent HMA treatment. Currently, combination therapies of azacitidine with lenalidomide appear to be promising thus making them ...

    Research Article last updated 06/20/2013 - 11:05am.

  6. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

    ... two randomized clinical trials, the demethylating agent azacitidine has demonstrated a reduced risk of transformation to AML, ... aims to provide practical recommendations for the use of azacitidine and the management of its side effects in patients with MDS, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. I Was Alone With MDS Until I Connected With Others on Social Media

    ... the exposure to infection.   This adjustment to azacitidine was a nightmare as I experienced more diarrhea, fever, pain and ...

    Patient Chronicle last updated 04/26/2018 - 9:40am.

  8. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

    ... investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after allogeneic stem-cell ...

    Research Article last updated 11/05/2012 - 8:57am.

  9. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

    ... This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Adverse effects of azacitidine: onset, duration, and treatment

    ... with survivals of close to only 1 year. The use of azacitidine , a DNA methyltransferase inhibitor, in this group of patients ...

    Research Article last updated 10/11/2011 - 5:58pm.